Adopting a strategic approach to managing PV activities for the mature portfolio
One approach many adopt is to work with outsourcing partners to support the regulatory (RA), pharmacovigilance (PV), and quality activities (QA) that are crucial to keeping the product on global markets while reducing the product maintenance costs involved.
Thinking global, acting local with pharmacovigilance expertise
Additionally, companies with products on the market in Europe must follow dedicated European pharmacovigilance regulations, e.g. they must have fully compliant and functional PV systems, overseen by a Qualified Person for Pharmacovigilance (QPPV).2
Rather than having full-time personnel on the ground in multiple global markets, companies often turn to outsourcing partners to support crucial regulatory and safety activities from a central hub, while also ensuring on-the-ground support for local activities.
Adopting a harmonized, forward-looking approach to PV
It also helps companies achieve strategic oversight of all pharmacovigilance responsibilities and paves the way for expanding into new markets without the need to bring on additional staff in those regions.
Another key consideration for companies is the ability to leverage digital innovation tools, such as artificial intelligence, to support key safety activities such as signal management. At the same time, however, investing in digital capabilities is cost-intensive and hard to justify for mature products. Outsourcing management of the mature portfolio, including essential PV activities, to a partner with digital capabilities and expertise gives biopharma companies access to those solutions, as and where it makes business sense.
Reducing complexity with an integrated PV approach
In one example, a German biopharmaceutical organization needed a comprehensive outsourced solution for PV tasks for its large portfolio of marketing authorizations. Key requirements included fully outsourced pharmacovigilance system administration, including a fully validated safety database, support for all operational PV activities, and effective coordination of its worldwide network of strategic partners.
The company turned to Cencora for a PV system that would consolidate its pharmacovigilance responsibilities under a single provider, serving multi-territory needs and providing strategic oversight. The partnership resulted in reduced complexity and streamlined safety activities – from management of the PV system to end-to-end pharmacovigilance oversight to audit and inspection readiness to ongoing intelligence for all drug safety and cross-functional issues.
Adopting an adaptable approach to pharmacovigilance outsourcing
For example, a U.S.-based company may seek a partner to support the QPPV requirements in Europe, leaving that partner to manage PV activities there. Alternatively, if the company has a European office to support central activities (such as the QPPV) but has no local expertise, it might seek a partner to cover local affiliate services rather than having to employ local contact personnel for each market to carry out local literature screening and perform local risk assessments, case intakes, and other local activities. As needs grow and as the portfolio matures, companies may choose to extend the outsourcing engagement to other service lines.
The emphasis is to seek support where it makes greatest strategic sense, such as where the company lacks resources to manage essential activities or where local expertise is required.
As products mature and the company’s focus shifts to new product development, the opportunity to expand the outsourcing relationship to achieve global holistic support across PV, regulatory, and quality can be leveraged – how, when and where it makes strategic business sense.
About the author:
Connect with our team
Sources
1. Big Pharma race to snap up biotech assets as $170 billion patent cliff looms, CNBC, 7 January 2026. Accessed 12 March 2026. https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
2. Pharmacovigilance system: questions and answers, EMA. Accessed 12 March 2026. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/pharmacovigilance-system-questions-answers
Related resources
[BEISPIEL SPOTLIGHT - BITTE LESEN]
BITTE ERSETZEN SIE DIESES SPOTLIGHT DURCH EIN PASSENDES INHALTSELEMENT!
Ändern Sie den zugehörigen Inhalt dieses Moduls, indem Sie unter /Website Settings/Shared Content/Global Banners eines der Full Image Spotlight-Inhaltselemente auswählen
Cencora.com stellt automatisierte Übersetzungen zur Verfügung, um das Lesen der Website in anderen Sprachen als Englisch zu erleichtern. Für diese Übersetzungen wurden angemessene Anstrengungen unternommen, um eine genaue Übersetzung zu liefern, jedoch ist keine automatisierte Übersetzung perfekt und auch nicht dazu gedacht, menschliche Übersetzer zu ersetzen. Diese Übersetzungen werden den Nutzern von Cencora.com als Service zur Verfügung gestellt und "wie besehen" zur Verfügung gestellt. Es wird keinerlei Garantie, weder ausdrücklich noch stillschweigend, für die Genauigkeit, Zuverlässigkeit oder Richtigkeit dieser Übersetzungen aus dem Englischen in eine andere Sprache übernommen. Einige Inhalte (z. B. Bilder, Videos, Flash usw.) können aufgrund der Einschränkungen der Übersetzungssoftware möglicherweise nicht genau übersetzt werden.
Jegliche Unstimmigkeiten oder Unterschiede, die bei der Übersetzung dieser Inhalte aus dem Englischen in eine andere Sprache entstehen, sind nicht bindend und haben keine rechtliche Wirkung für die Einhaltung, Durchsetzung oder andere Zwecke. Wenn Fehler festgestellt werden, kontaktieren Sie unsbitte . Wenn Sie Fragen zur Richtigkeit der in diesen Übersetzungen enthaltenen Informationen haben, lesen Sie bitte die englische Version der Seite.
